{"id":"W2995845770","doi":"10.1016/j.jval.2019.09.311","title":"PCN114 ASSESSMENT OF THE SURVIVAL BENEFIT AND COST IMPACT OF NEW TREATMENTS FOR KEY ANSCLC BIOMARKERS USING THE ITEN MODEL","year":2019,"lang":"en","type":"article","venue":"Value in Health","topic":"Economic and Financial Impacts of Cancer","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Dabrafenib; Alectinib; Medicine; Trametinib; Oncology; Pembrolizumab; Osimertinib; Lung cancer; Internal medicine; Erlotinib; Vemurafenib; Crizotinib; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00243654,0.0006405184,0.00103813,0.0009354273,0.0002598579,0.001213943,0.00132383,0.001062745,0.01360917],"category_scores_gemma":[0.00713201,0.000354049,0.001604688,0.000841774,0.0004085201,0.0007533655,0.0006643473,0.001303048,0.0007856259],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0019997,"about_ca_system_score_gemma":0.001520726,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.02752503,"about_ca_topic_score_gemma":0.0174891,"domain_scores_codex":[0.9994147,0.0003176948,0.00001453651,0.00007644011,0.00007420915,0.0001024177],"domain_scores_gemma":[0.9968212,0.002485044,0.000156325,0.0001284431,0.0002844243,0.0001244296],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","study_design_scores_codex":[0.0003317258,0.0000732927,0.003888114,0.00006225695,0.0001235722,0.00006740021,0.000009133266,0.9735242,0.000115587,0.009220878,0.003088121,0.009495758],"study_design_scores_gemma":[0.00008413379,0.0001314176,0.002053119,0.00002391293,0.00005703721,0.00005459575,0.00001732274,0.9882283,0.0001273029,0.007761397,0.001452144,0.000009349812],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.7222096,0.002469511,0.1623548,0.005798684,0.0004007212,0.0003980341,0.01414122,0.0004750391,0.09175245],"genre_scores_gemma":[0.9731367,0.0003618476,0.00665124,0.0002856157,0.00005510694,0.0001463426,0.002812427,0.00004761996,0.01650311],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02752503,"threshold_uncertainty_score":0.05472964,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.119171668890072,"score_gpt":0.3461158137998317,"score_spread":0.2269441449097597,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}